Empasug ST 100/10
| Brand | Empasug ST 100/10 |
|---|---|
| Composition | Empagliflozin 10 mg + Sitagliptin 100 mg |
| Packing | 10x10 |
| Pack Type | Tab |
For pharmaceutical trade buyers, not patient or consumer sales. This record reproduces company product information, not medical advice. Current product availability and terms are confirmed by Intra Life.
Enquire about Empasug ST 100/10Indication
Management of type 2 diabetes mellitus in adults requiring combination therapy, alongside diet and exercise, to improve blood glucose control.
Mechanism of action
Sitagliptin inhibits DPP-4, increasing active incretin hormones and enhancing glucose-dependent insulin release while reducing glucagon levels. Empagliflozin inhibits SGLT2 in the kidneys, reducing glucose reabsorption and increasing urinary glucose excretion.
For pharmaceutical trade information, not a patient-specific prescription. Use the current approved product insert and the prescribing clinician's directions.
Empasug ST 100/10 for B2B enquiries
Distributors, stockists, medical stores, hospitals and PCD franchise buyers can share their city, quantity and product requirements. Ask the team for current supply, packing and trade terms.
Ask for trade details on WhatsAppKeep exploring
Browse related brand searches · All published products · Browse divisions
Explore products with a matching ingredient term
For catalogue browsing only, not substitutions. Formulations and strengths differ.
SITANOW-50
SUGAVIA-M 500
SUGAVIA-100
SITANOW-M 1000